BEST-Fluids研究方案:比较Plasma-Lyte 148与0.9%盐水对 deceased donor 肾移植延迟移植物功能影响的实用随机对照试验
BEST-Fluids是一项研究者发起的、实用、基于注册登记的多中心双盲随机对照试验,计划在澳大利亚和新西兰招募800例 deceased donor 肾移植受者,1:1随机接受围手术期至术后48小时静脉Plasma-Lyte 148或0.9%盐水,主要结局为移植后7天内需要透析的延迟移植物功能发生率,随访1年。
要点
- 比较平衡低氯溶液Plasma-Lyte 148与0.9%盐水对 deceased donor 肾移植延迟移植物功能的影响。
- 计划招募800例,1:1随机,干预至术后48小时或不再需要液体为止,随访1年。
- 主要结局为移植后7天内透析定义的延迟移植物功能发生率。
核心结论
- Plasma-Lyte 148是否比0.9%盐水更安全并改善 deceased donor 肾移植后肾功能尚不清楚,BEST-Fluids旨在回答该问题。
研究设计与样本
- 研究者发起的实用、基于注册登记的多中心双盲随机对照试验。
- 计划从2018年1月起在澳大利亚和新西兰用3年招募800例接受 deceased donor 肾移植的受者。
- 参与者1:1随机接受静脉Plasma-Lyte 148或0.9%盐水,围手术期至移植后48小时或不再需要液体为止,以先到者为准。
- 随访1年,使用澳大利亚和新西兰透析与移植(ANZDATA)注册登记进行入组、随机和随访。
关键数值与推荐
- 主要结局为延迟移植物功能发生率,定义为移植后7天内需要透析。
- 次要结局包括早期移植肾功能(透析持续时间与不需透析时移植物功能改善速率的复合指标)、高钾血症、死亡率、移植物存活、移植物功能、生活质量、医疗资源使用和成本效果。
临床怎么用
- 若Plasma-Lyte 148有效,这种简单、廉价的平衡低氯静脉液体替换0.9%盐水的做法可在全球大多数移植中心推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney transplantation and is associated with inferior outcomes and higher costs. Intravenous fluids given during and after transplantation may affect the risk of poor kidney function after transplant. The most commonly used fluid, isotonic sodium chloride (0.9% saline), contains a high chloride concentration, which may be associated with acute kidney injury, and could increase the risk of delayed graft function. Whether using a balanced, low-chloride fluid instead of 0.9% saline is safe and improves kidney function after deceased donor kidney transplantation is unknown. METHODS: BEST-Fluids is an investigator-initiated, pragmatic, registry-based, multi-center, double-blind, randomized controlled trial. The primary objective is to compare the effect of intravenous Plasma-Lyte 148 (Plasmalyte), a balanced, low-chloride solution, with the effect of 0.9% saline on the incidence of delayed graft function in deceased donor kidney transplant recipients. From January 2018 onwards, 800 participants admitted for deceased donor kidney transplantation will be recruited over 3 years in Australia and New Zealand. Participants are randomized 1:1 to either intravenous Plasmalyte or 0.9% saline peri-operatively and until 48 h post-transplant, or until fluid is no longer required; whichever comes first. Follow up is for 1 year. The primary outcome is the incidence of delayed graft function, defined as dialysis in the first 7 days post-transplant. Secondary outcomes include early kidney transplant function (composite of dialysis duration and rate of improvement in graft function when dialysis is not required), hyperkalemia, mortality, graft survival, graft function, quality of life, healthcare resource use, and cost-effectiveness. Participants are enrolled, randomized, and followed up using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry. DISCUSSION: If using Plasmalyte instead of 0.9% saline is effective at reducing delayed graft function and improves other clinical outcomes in deceased donor kidney transplantation, this simple, inexpensive change to using a balanced low-chloride intravenous fluid at the time of transplantation could be easily implemented in the vast majority of transplant settings worldwide. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry: ACTRN12617000358347. Registered on 8 March 2017. ClinicalTrials.gov: NCT03829488. Registered on 4 February 2019.
引用
- Collins MG, Fahim MA, Pascoe EM, et al. Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9% saline on delayed graft function in deceased donor kidney transplantation. Trials. 2020. PMID: 32450917. doi:10.1186/s13063-020-04359-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。